GlassScriptPhysician profile
Noga Harizman
NPI 1588697908
$7,134.33
in general payments reported to CMS, 2019-2025
16 companies · $671 in 2025
The $671 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $495 · 2020: $411 · 2021: $180 · 2022: $488 · 2023: $769 · 2024: $4,121 · 2025: $671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $2,500 · Food and Beverage: $2,361 · Consulting Fee: $700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $2,500.00 |
| Food and Beverage | $2,360.86 |
| Consulting Fee | $700.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| New World Medical,INC. | $3,425.72 | 2019-2024 | Ahmed Glaucoma Valve, Kahook Dual Blade, Streamline |
| Alcon Vision LLC | $1,067.23 | 2022-2025 | Clareon, Tryptyr, Centurion |
| Thea Pharma INC. | $700.00 | 2024 | Iyuzeh |
| Sight Sciences, INC. | $577.57 | 2020-2023 | Omni Surgical System |
| Abbvie INC. | $295.43 | 2024-2025 | |
| Carl Zeiss Meditec Cataract Technology INC. | $192.37 | 2023 | |
| Allergan, INC. | $149.03 | 2019 | |
| Glaukos Corporation | $139.10 | 2025 | Istent Infinite |
| Harrow Eye, LLC | $134.12 | 2024 | Vevye |
| Omeros Corporation | $118.37 | 2019 | |
| Amgen INC. | $76.13 | 2024 | Tepezza |
| Bausch & Lomb Americas INC. | $67.55 | 2023-2025 | Vyzulta, Xiidra, Miebo |
| Johnson & Johnson Surgical Vision, INC. | $59.60 | 2024 | Tecnis Simplicity |
| Iridex Corporation | $58.33 | 2020 | |
| Horizon Therapeutics Plc | $45.66 | 2022-2023 | Tepezza |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $28.12 | 2025 | Oxervate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noga Harizman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.